Mednax Inc (MD)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -60,408 | 93,538 | 102,875 | 101,729 | 66,335 | 84,192 | 84,259 | 92,134 | 130,964 | 19,152 | -52,687 | -760,134 | -796,488 | -722,861 | -1,937,737 | -1,273,546 | -1,497,706 | -1,446,823 | -125,328 | -37,671 |
| Total stockholders’ equity | US$ in thousands | 849,061 | 967,985 | 942,375 | 909,771 | 891,632 | 858,667 | 845,430 | 877,076 | 896,487 | 845,466 | 808,906 | 766,759 | 747,485 | 804,761 | 826,570 | 1,487,400 | 1,499,000 | 1,479,360 | 2,725,030 | 2,779,810 |
| ROE | -7.11% | 9.66% | 10.92% | 11.18% | 7.44% | 9.80% | 9.97% | 10.50% | 14.61% | 2.27% | -6.51% | -99.14% | -106.56% | -89.82% | -234.43% | -85.62% | -99.91% | -97.80% | -4.60% | -1.36% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-60,408K ÷ $849,061K
= -7.11%
Pediatrix Medical Group Inc's return on equity (ROE) has fluctuated over the past eight quarters.
In Q1 2023, the ROE was 11.18%, showing a strong performance, but it decreased to 10.92% in Q2 2023 and further declined to 9.66% in Q3 2023. However, the company experienced a significant drop in ROE to -7.11% in Q4 2023, indicating a negative return for shareholders during that period.
Comparing the current ROE figures to the previous year, there was a slight improvement from 7.44% in Q4 2022 to 9.66% in Q3 2023. However, the ROE in Q4 2023 at -7.11% reveals a concerning trend of declining profitability and efficiency in generating returns for shareholders.
Overall, the inconsistent performance in ROE over the past quarters suggests that Pediatrix Medical Group Inc may be facing challenges in effectively utilizing shareholders' equity to generate profits. It is essential for the company to address the factors contributing to the negative ROE and work towards improving their financial performance to enhance shareholder value.
Peer comparison
Dec 31, 2023